PMID- 24839444
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140519
LR  - 20211021
IS  - 1687-9260 (Print)
IS  - 1687-9279 (Electronic)
IS  - 1687-9260 (Linking)
VI  - 2014
DP  - 2014
TI  - The relationship of antibodies to modified citrullinated vimentin and markers of 
      bone and cartilage destruction in rheumatoid arthritis.
PG  - 464585
LID - 10.1155/2014/464585 [doi]
LID - 464585
AB  - Objective. To make individualised decisions regarding treatment is one of the 
      most important challenges in clinical practise, and identification of sensitive 
      and specific markers of prognosis is an important research question. The main 
      objective of this study was to evaluate relationships between the level of 
      autoantibodies, radiographic changes and laboratory markers of bone, and 
      cartilage destruction. Methods. A total of 114 RA patients were examined. The 
      serum concentration of IgM RF, antibodies to cyclic citrullinated peptide 
      (anti-CCP), modified citrullinated vimentin (anti-MCV), matrix metalloproteinase 
      3 (MMP-3), and cartilage oligomeric matrix protein (COMP, ng/mL) were measured. 
      The van der Heijde-modified Sharp Score was used to quantify the radiologic 
      changes. Results. Among the patients who were high-positive for anti-MCV, the 
      value of total modified Sharp score (mTSS) (96.5; 66-120) was higher as well as 
      the joint space narrowing (82; 60.5-105.5), and a higher level of MMP-3 was 
      recorded more frequently (56%) in comparison with negative/low-positive patients 
      (57; 31-88, 50; 29-82, 31% resp., P < 0.05). The level of COMP was also higher 
      among patients high-positive for anti-MCV (9.7; 8.1-13.1 and 6.8; 5.4-10.7, 
      resp., P = 0.02). Conclusion. A high positive level of anti-MCV as contrasted 
      with anti-CCP and IgM RF is associated with more pronounced destructive changes 
      in the joints.
FAU - Avdeeva, A S
AU  - Avdeeva AS
AD  - Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34 A, Moscow 
      115522, Russia.
FAU - Aleksandrova, E N
AU  - Aleksandrova EN
AD  - Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34 A, Moscow 
      115522, Russia.
FAU - Novikov, A A
AU  - Novikov AA
AD  - Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34 A, Moscow 
      115522, Russia.
FAU - Smirnov, A V
AU  - Smirnov AV
AD  - Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34 A, Moscow 
      115522, Russia.
FAU - Cherkasova, M V
AU  - Cherkasova MV
AD  - Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34 A, Moscow 
      115522, Russia.
FAU - Nasonov, E L
AU  - Nasonov EL
AD  - Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34 A, Moscow 
      115522, Russia.
LA  - eng
PT  - Journal Article
DEP - 20140415
PL  - United States
TA  - Int J Rheumatol
JT  - International journal of rheumatology
JID - 101519204
PMC - PMC4009265
EDAT- 2014/05/20 06:00
MHDA- 2014/05/20 06:01
PMCR- 2014/04/15
CRDT- 2014/05/20 06:00
PHST- 2014/01/05 00:00 [received]
PHST- 2014/02/26 00:00 [revised]
PHST- 2014/03/13 00:00 [accepted]
PHST- 2014/05/20 06:00 [entrez]
PHST- 2014/05/20 06:00 [pubmed]
PHST- 2014/05/20 06:01 [medline]
PHST- 2014/04/15 00:00 [pmc-release]
AID - 10.1155/2014/464585 [doi]
PST - ppublish
SO  - Int J Rheumatol. 2014;2014:464585. doi: 10.1155/2014/464585. Epub 2014 Apr 15.